drugset
drugset / Trial / NCT05440942

Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma

NCT05440942 ↗

Phase 1 Completed 28 enrolled Peter Hosein, MD Incyte Corporation · collabNovartis Pharmaceuticals · collabUniversity of Miami Sylvester Comprehensive Cancer Center · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this research is to test whether a combination treatment of Trametinib, Retifanlimab, and Ruxolitinib (TR\^2) will reduce tumor size in patients with metastatic pancreatic ductal adenocarcinoma (PDAC).

Timeline

Start
2023-01-19
Primary completion
2025-05-30
Completion
2025-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Retifanlimab Monoclonal antibody 500 mg Intravenous
Subject Ruxolitinib Small molecule 5 mg Oral
Subject Ruxolitinib Small molecule 10 mg Oral
Subject Ruxolitinib Small molecule 15 mg Oral
Subject Trametinib Small molecule 1 mg Oral
Subject Trametinib Small molecule 1.5 mg Oral
Subject Trametinib Small molecule 2 mg Oral

Indications

pancreatic ductal adenocarcinoma